PathomIQ
Healthcare Software · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
19925 Stevens Creek Blvd Ste 100, Cupert...Website
www.pathomiq.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About PathomIQ
PATHOMIQ is a pioneering company that leverages an AI-driven platform to enhance precision medicine in oncology. Their innovative technology integrates morphology and genomics to predict treatment responses for prostate, breast, and bladder cancers, enabling personalized treatment plans based on individual genomic profiles. The platform is designed for healthcare professionals, providing rapid, cost-effective, and accurate predictions while preserving tissue integrity for advanced analysis. PATHOMIQ aims to transform cancer treatment by delivering interpretable insights that improve patient outcomes and reduce side effects.Explore more
PathomIQ Org Chart
HM
Principal AI Scientist
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PathomIQ your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
PathomIQ, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at PathomIQ
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if PathomIQ is spiking on competitors!
Funding: Get notified immidiatlly once PathomIQ has new funding data
Earning: See what the market has to say on PathomIQ recently announced quarterly report
Check if PathomIQ has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when PathomIQ launches new products
Click to see if PathomIQ had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at PathomIQ
Find 3 more new buyers
Compare Similar Companies to PathomIQ
Compare insights from companies similar to PathomIQ, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
PathomIQ is experiencing very low activity levels compared to other companies in the Software sector.
What does this means?
PathomIQ is drawing exceptional interest within the Software industry, suggesting notable developments or strong market momentum, learn more about PathomIQ.
PathomIQ Tech Stack
A closer look at the technologies used by PathomIQ
PathomIQ News & Media
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
Myriad Genetics entered into a strategic collaboration with PATHOMIQ to exclusively license its AI technology platform for prostate cancer in the US.PathomIQ and Neuberg Diagnostics Partner to Deploy Novel AI-based Prognostic and Predictive Biomarker tests in Clinical Practice
CUPERTINO, Calif., June 6, 2023 /PRNewswire/ -- PathomIQ INC. and Neuberg Diagnostics, today announced a multi-year partnership to accelerate clinical deployment of PATHOMIQ's AI based prognostic and predictive biomarkers as a Lab Developed Test (LDT) which will be available in Neuberg...PathomIQ's AI-powered tool shows promise in assessing risk for metastasis in non-metastatic castration-resistant prostate cancer (nmCRPC)
CUPERTINO, Calif., June 6, 2023 /PRNewswire/ -- New data released today at the American Society of Clinical Oncology (ASCO) Annual Meeting highlighted the application of PathomIQ Inc.'s PATHOMIQ_PRAD AI test to assess the risk for metastasis in non-metastatic castration-resistant prostate...PathomIQ Announces Data Presentation on an AI-powered tool that Predicts Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy at the San Antonio Breast Cancer Symposium (SABCS) 2022
CUPERTINO, Calif., Dec. 8, 2022 /PRNewswire/ -- PathomIQ Inc., today announced the application of an AI-powered tool to predict response to Neoadjuvant Chemotherapy (NAC) in patients with Triple Negative Breast Cancer (TNBC) presented at the San Antonio Breast Cancer Symposium (SABCS),...
Read more news
Top Healthcare Software Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding PathomIQ
Sign Up For FreeTo access detailed company insights
PATHOMIQ is a pioneering company that leverages an AI-driven platform to enhance precision medicine in oncology. Their innovative technology integrates morphology and genomics to predict treatment responses for prostate, breast, and bladder cancers, enabling personalized treatment plans based on individual genomic profiles. The platform is designed... Read More
